Nivolumab & AVDPhase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07551583

Conditions

Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Nivolumab

Doxorubicin Hydrochloride

Vinblastine

Dacarbazine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-01. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-08-25.